GSK awaits Nucala decision after FDA target date passes
The FDA is still reviewing a label expansion for GSK’s respiratory drug Nucala in chronic obstructive pulmonary disease despite the May 7 target date for a decision, the company confirmed to ...
The FDA is still reviewing a label expansion for GSK’s respiratory drug Nucala in chronic obstructive pulmonary disease despite the May 7 target date for a decision, the company confirmed to ...
